Primary Ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.

Xu Chen; Hong-ling Liu; Jin-sui Wang; Feng-hui Zhao

Return

Primary Ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.

Author: Xu CHEN ¹ ; Hong-Ling LIU ² ; Jin-Sui WANG ¹ ; Feng-Hui ZHAO ¹
Author Information

1. Department of Pathology, Gansu Provincial Hospital, Lanzhou 730000, China.
2. Department of Occupational Medicine, Third Gansu Provincial Hospital, Lanzhou 730000, China.
Publication Type:Journal Article
Keywords: adjuvant chemotherapy; primary ovarian small cell carcinoma of pulmonary type; sex-determining region of Y chromosome-related high-mobility-group box 2; small cell carcinoma of the ovary
MeSH: Female; Humans; Young Adult; Adult; Middle Aged; Aged; Aged, 80 and over; Carcinoma, Small Cell/pathology*; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms/therapy*; Prognosis
From: Chinese Medical Sciences Journal 2023;38(2):130-137
CountryChina
Language:English
Abstract: Objective Primary ovarian small cell carcinoma of pulmonary type (SCCOPT) is a rare ovarian tumor with a poor prognosis. The platinum-based chemotherapy is the standard treatment. However, there is little research on the clinical characteristics of SCCOPT and the potential benefits of other treatments due to its low incidence. The study aims to investigate clinicopathological characteristics and treatment of SCCOPT.Methods We summarized the clinical, imaging, laboratorical and pathological characteristics of 37 SCCOPT cases, in which 6 cases were admitted to the Gansu Provincial Hospital from the year of 2008 to 2022 and 31 cases reported in 17 English and 3 Chinese literatures.Results The median age of the studied SCCOPT cases (n=37) was 56.00 (range, 22-80) years. Almost 80% of them had a stage Ⅲ or Ⅳ tumor. All patients underwent an operation and postoperative chemotherapy. Nevertheless, all cases had a poor prognosis, with a median overall survival time of 12 months. Immunohistochemically, the SCCOPT of all patients showed positive expressions of epithelial markers, such as CD56 and sex-determining region of Y chromosome-related high-mobility-group box 2 (SOX-2), and negative expressions of estrogen receptor, progesterone receptor, vimentin, Leu-7, and somatostatin receptor 2. The tumor of above 80% cases expressed synaptophysin. Only a few cases expressed neuron-specific enolase, chromogranin A, and thyroid transcription factor-1. Conclusions SCCOPT had a poor prognosis. SOX-2 could be a biomarker to be used to diagnose SCCOPT.